{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:16:49Z","timestamp":1790083009069,"version":"4.0.1"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.2967\/jnumed.122.264770","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T16:20:20Z","timestamp":1688660420000},"page":"1431-1438","source":"Crossref","is-referenced-by-count":15,"title":["Dual-Time-Point Posttherapy<sup>177<\/sup>Lu-PSMA-617 SPECT\/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients\u2019 Outcome"],"prefix":"10.2967","volume":"64","author":[{"given":"Manuela","family":"Straub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kupferschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Maria","family":"Serna Higuita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weissinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"2023091409501487000_64.9.1431.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023091409501487000_64.9.1431.2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023091409501487000_64.9.1431.3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023091409501487000_64.9.1431.4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR."},{"key":"2023091409501487000_64.9.1431.5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","article-title":"Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis","volume":"43","author":"Kim","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2023091409501487000_64.9.1431.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023091409501487000_64.9.1431.7","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/RLU.0000000000004222","article-title":"Outcome of 177Lu-PSMA radionuclide treatment in advanced prostate cancer and its association with clinical parameters: a single-center experience","volume":"47","author":"Has Simsek","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2023091409501487000_64.9.1431.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263159"},{"key":"2023091409501487000_64.9.1431.9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin Nucl Med."},{"key":"2023091409501487000_64.9.1431.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2023091409501487000_64.9.1431.11","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023091409501487000_64.9.1431.12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13139-019-00588-9","article-title":"Clinical applications of technetium-99m quantitative single-photon emission computed tomography\/computed tomography","volume":"53","author":"Lee","year":"2019","journal-title":"Nucl Med Mol Imaging."},{"key":"2023091409501487000_64.9.1431.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.247312"},{"key":"2023091409501487000_64.9.1431.14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"2023091409501487000_64.9.1431.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023091409501487000_64.9.1431.16","doi-asserted-by":"crossref","first-page":"627379","DOI":"10.3389\/fonc.2020.627379","article-title":"Metastatic spread in prostate cancer patients influencing radiotherapy response","volume":"10","author":"Klusa","year":"2021","journal-title":"Front Oncol."},{"key":"2023091409501487000_64.9.1431.17","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20889"},{"key":"2023091409501487000_64.9.1431.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.240408"},{"key":"2023091409501487000_64.9.1431.19","first-page":"1","article-title":"Assessment of skeletal tumor load in metastasized castration-resistant prostate cancer patients: a review of available methods and an overview on future perspectives","volume":"5","author":"Fiz","year":"2018","journal-title":"Bioengineering (Basel)."},{"key":"2023091409501487000_64.9.1431.20","doi-asserted-by":"crossref","first-page":"3905216","DOI":"10.1155\/2017\/3905216","article-title":"Tumor burden and intraosseous metabolic activity as predictors of bone marrow failure during radioisotope therapy in metastasized prostate cancer patients","volume":"2017","author":"Fiz","year":"2017","journal-title":"BioMed Res Int."},{"key":"2023091409501487000_64.9.1431.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2023091409501487000_64.9.1431.22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-1204-9932","article-title":"Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer","volume":"59","author":"G\u00f6tz","year":"2020","journal-title":"Nuklearmedizin."},{"key":"2023091409501487000_64.9.1431.23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MNM.0000000000001535","article-title":"Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review","volume":"43","author":"Nautiyal","year":"2022","journal-title":"Nucl Med Commun."},{"key":"2023091409501487000_64.9.1431.24","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023091409501487000_64.9.1431.25","first-page":"417","article-title":"The feasibility of 64Cu-PSMA I&T PET for prostate cancer","volume":"37","author":"Lee","year":"2022","journal-title":"Cancer Biother Radiopharm."},{"key":"2023091409501487000_64.9.1431.26","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","article-title":"64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer","volume":"48","author":"Liu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023091409501487000_64.9.1431.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.250597"},{"key":"2023091409501487000_64.9.1431.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.226498"},{"key":"2023091409501487000_64.9.1431.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2023091409501487000_64.9.1431.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T16:52:28Z","timestamp":1694710348000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.2967\/jnumed.122.264770"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264770","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}